14 Mar 2020

ABOUT 4 IN 10 ADULTS IN THE U.S. ARE AT GREATER RISK OF DEVELOPING SERIOUS ILLNESS IF INFECTED WITH CORONAVIRUS

  Based on current understanding of risk, forty-one percent of adults ages 18 and older in the U.S. have a higher risk of developing more serious illness if they become infected with the virus that causes COVID-19, because they are older or have serious underlying health conditions, or both, according

0
11 Mar 2020

THROMBOLEX INC. BASHIR ENDOVASCULAR CATHETER FIH TRIAL RESULTS REPORTED AT AVF MEETING

    Thrombolex Inc., a medical device company focused on the design, development and manufacture of endovascular therapies for the treatment of arterial and venous thromboembolic disorders, has announced that its First-In-Human (FIH) trial confirms the early safety and feasibility of using the Bashir Endovascular Catheter for pharmaco-mechanical catheter-directed thrombolysis

0
18 Feb 2020

GEOFF MARTHA TO REPLACE OMAR ISHRAK AT MEDTRONIC APRIL 27

       Geoff Martha, who leads Medtronic’s restorative therapies group and previously oversaw the company’s spine business, will succeed Omar Ishrak as president and CEO on April 27. Ishrak ‘s nearly 10-year tenure as chairman and CEO of Medtronic will come to an end when he retires April 26.

0
12 Feb 2020

FDA OKs HYPERFINE’s BEDSIDE MRI

  The FDA has approved 510 (k) clearance for the Hyperfine Research Inc. bedside Magnetic Resonance Imaging (MRI) system, the world’s first bedside MRI. The Hyperfine system is 20 times lower cost, 35 times lower power consumption, and 10 times less weight than today’s fixed conventional MRI systems. Jonathan Rothberg,

0
12 Feb 2020

THE IMPORTANCE OF DILUENTS IN SCLEROSANTS

By Ronald Bush, MD, FACS An advantage of having access to a histology lab cannot be overstated. The ability to scientifically study various venous issues is possible. One study we have recently completed and are now submitting is comparing the critical micelle concentration (CMC) of both Sotradecol (STS) and Polidocanol

0
12 Feb 2020

VENOUS SYMPOSIUM 2020: 29 sessions and new aesthetic vein course offered March 18-21

  The Venous Symposium 2020 will convene its 11th annual conference March 19-21 at the Sheraton New York Times Square Hotel, including a Latin language program. VS 2020 has scheduled 29 educational sessions, as well as an aesthetic vein course before the conference begins. In addition, VS also welcomes physicians

0
stack of VTN issues - cropped
20 Jan 2020

VTN ADVERTISING OPPORTUNITY TO BUY OR SELL USED MEDICAL EQUIPMENT

Vein Therapy News has added an economical new advertising opportunity to get rid of  or acquire used medical devices: “Buy or Sell Used Medical Equipment.” Physicians have asked for a forum for moving their older medical equipment that is taking up room in their offices. Publications & Communications Inc., Vein

0
03 Dec 2019

IAC CONDUCTS ACCREDITATION PERCEPTIONS SURVEY

Authentic Testing has been engaged by the Intersocietal Accreditation Commission (IAC) to understand perceptions related to the value of imaging and procedural accreditation across multiple medical specialties. The results of the survey will help guide future quality initiatives to meet the needs of the medical community and to improve the

0
26 Jun 2019

 ANGIODYNAMICS SELLS NAMIC fluid management portfolio

AngioDynamics Inc., a provider of innovative, minimally invasive medical devices for oncology, vascular access and peripheral vascular disease, has agreed to sell its NAMIC fluid management portfolio to Medline Industries Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The

0
26 Jun 2019

CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

0